Medlab Middle East is approaching. Come and visit us to learn more about our upcoming NEW products- Traumatic Brain Injury CLIA test (GFAP and UCH-L1)! We are your trusted partner for Fast, Safe, Accurate, and Affordable Emergency Room Tests!
BioCheck, Inc.
生物技术研究
South San Francisco,California 964 位关注者
Diagnostic Solutions For Better Patient Outcomes
关于我们
BioCheck develops and manufactures high-quality immunoassay kits for the worldwide healthcare markets in their cGMP and ISO 13485 certified facility in the San Francisco Bay Area. BioCheck also provides custom immunoassay development and contract manufacturing services to the diagnostic and research industries.
- 网站
-
http://biocheckinc.com
BioCheck, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- South San Francisco,California
- 类型
- 私人持股
- 领域
- Biotechnology、ELISA、Chemilluminescence和Chemiluminescence
地点
-
主要
425 Eccles Ave
US,California,South San Francisco,94080
BioCheck, Inc.员工
-
Grace Ma
Office Manager
-
David Peretz
Director of Diagnostics R&D
-
Wei Fu
Senior Vice President of antibody development at OriGene Technologies Inc.
-
Gangadhar Karipe
12 + years of experience in IVD | Product support | MENA & Indian Sub-Continent | Service & Applications at DRG Instruments GmbH-Germany a…
动态
-
It’s that time of year in the US when we are called to count our blessings. BioCheck-DRG customers are the reason we thrive. So, in the spirit of the season, we want to send a huge THANK YOU to you all. Thank you so much for your loyalty, your feedback, and your support. Wishing you and your loved ones a wonderful Thanksgiving filled with warmth and happiness!
-
-
Alzheimer’s Disease is known as a leading cause of death in older adults globally. Alzheimer’s is a brain disease that causes problems with memory, thinking and behavior. It is the most common cause of dementia resulting in memory loss and other cognitive abilities serious enough to interfere with daily life. As we recognize Alzheimer’s Awareness Month, it is important to understand the key biomarkers such as GFAP and UCH-L1 that support the early diagnosis of Alzheimer’s. BioCheck-DRG is committed to support the early detection of Alzheimer’s Disease. We believe human’s quality of life can be preserved through neuroscience innovation. https://lnkd.in/gQiSBQ5m https://lnkd.in/g7K7ezqn We can make this happen. We can make a difference.
-
-
We hope you had a great time at MEDICA and arrived home safely. It was great to meet everyone at the show! Our company’s focus on innovation for human neuroscience gained lots of interests. We look forward to being your trusted partner in providing breakthrough technology for assessing human brain health and assuring the quality of life is preserved. Contact us for more information about our GFAP and UCH-L1 antibodies. We cannot wait to see you again soon at Medlab Middle East in Dubai. Save the date! 3-6 February 2025.
-
DRG Instruments GmbH A BioCheck Company will be at MEDICA from 11/11-11/14. We are excited to meet you there and talk about our products and services that can benefit your needs. Contact us now at raeder@drg-diagnostics.de to schedule a one-on-one time with our team. Visit us at Hall 3/A69. We look to seeing you there soon!
-
-
Today BioCheck and DRG Instruments GmbH presented at G-SPARC 2024 Global South Conference on Infection Prevention and Control & Antimicrobial Stewardship (G-SPARC) in Hyderabad, Telagana-India. We are proud to have one of our Scientists, Laharika Katamoni, presented our global company collaboration project on using Therapeutic Drug Monitoring assays to optimize antibiotic dosing, reducing toxicity and improving patient outcomes, particularly for critically ill patients. You can learn more about our continuous growing Therapeutic Drug Monitoring assays by contacting us or visiting our website. #AntimicrobialResistance #InfectionControl #TherapeuticDrugMonitoring #AntibioticStewardship #Biotechnology #GSPARC2024 #HealthcareInnovation #PrecisionMedicine #GlobalHealth.